Insys Therapeutics, Inc. (NASDAQ:INSY)‘s stock had its “hold” rating reiterated by Oppenheimer Holdings, Inc. in a research report issued on Monday.
Several other research firms have also commented on INSY. Zacks Investment Research upgraded Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, July 12th. BidaskClub upgraded Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Piper Jaffray Companies set a $10.00 target price on Insys Therapeutics and gave the company a “hold” rating in a research report on Wednesday, July 26th. Royal Bank Of Canada decreased their target price on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. Finally, TheStreet lowered Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $10.13.
Insys Therapeutics (NASDAQ:INSY) opened at 5.15 on Monday. Insys Therapeutics has a one year low of $4.10 and a one year high of $15.06. The stock’s market cap is $374.38 million. The firm’s 50-day moving average is $8.23 and its 200 day moving average is $10.57.
Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The business had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. During the same quarter in the prior year, the firm posted $0.13 EPS. The business’s quarterly revenue was down 38.4% compared to the same quarter last year. On average, analysts anticipate that Insys Therapeutics will post ($0.33) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/01/insys-therapeutics-inc-insy-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
In other news, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $8.93 per share, for a total transaction of $156,275.00. Following the acquisition, the insider now owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Saeed Motahari acquired 5,500 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the acquisition, the chief executive officer now directly owns 15,400 shares in the company, valued at approximately $137,368. The disclosure for this purchase can be found here. Company insiders own 67.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in INSY. Wells Fargo & Company MN lifted its holdings in Insys Therapeutics by 30.3% in the 1st quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock valued at $289,000 after purchasing an additional 6,407 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in Insys Therapeutics in the 1st quarter valued at $172,000. Parametric Portfolio Associates LLC lifted its holdings in Insys Therapeutics by 34.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 25,712 shares of the specialty pharmaceutical company’s stock valued at $270,000 after purchasing an additional 6,600 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Insys Therapeutics by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock valued at $480,000 after purchasing an additional 12,561 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in Insys Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 953 shares in the last quarter. Institutional investors own 25.48% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
What are top analysts saying about Insys Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insys Therapeutics Inc. and related companies.